RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:313846

Familial cutaneous telangiectasia and oropharyngeal cancer predisposition syndrome

medium confidenceDisorder

Publications

202

60.3th percentile

Trials

0

Interventional, condition-specific

Researchers

180

Distinct authors in sample

Gene link

ATR

Moderate

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare, inherited cancer-predisposing syndrome characterized by an early development of cutaneous telangiectasia, mild dental and nail anomalies, patchy alopecia over the affected skin areas and increased lifetime risk for oropharyngeal cancer. Other types of cancer have also been reported.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (1)

familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Moderate — ATR

  2. LiteraturePresent

    202 matched papers (126 in last 10 years) Source

  3. Phenotype characterisedPresent

    17 HPO annotations (e.g. Livedo; Unusual fungal nail infection; Facial telangiectasia) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Probably — there is moderate evidence for ATR.

GenCC classification: Moderate.

Phenotypes (Monarch / HPO)

17

Associated phenotypes · MONDO:0013806

  • Livedo
  • Unusual fungal nail infection
  • Facial telangiectasia
  • Onycholysis
  • Telangiectasia

Showing 5 of 17 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

202

202 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

202 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

126 in the last 10 years · medium confidence · 60.3th percentile (publications denominator)

Phrase hits: 17 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

180

Distinct author names in 17 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Bannon SA2 papers · 2016

    Department of Clinical Cancer Genetics, University of Texas MD Anderson Cancer Center, Houston, TX.

    Papers in Europe PMC
  2. 02
    DiNardo CD2 papers · 2016

    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: cdinardo@mdanderson.org.

    Papers in Europe PMC
  3. 03
    Godley LA2 papers · 2026

    Section of Hematology/Oncology, Department of Medicine, Comprehensive Cancer Research Center, University of Chicago, Chicago, IL.

    Papers in Europe PMC
  4. 04
    Gyawali CP2 papers · 2018

    Division of Gastroenterology, Washington University School of Medicine, St Louis, MO.

    Papers in Europe PMC
  5. 05
    Akçin ÖÇ1 paper · 2026

    Department of Medical Genetics, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

    Papers in Europe PMC
  6. 06
    Al Hinai K1 paper · 2022

    Oman Medical Specialty Board Council, Sultanate of Oman.

    Papers in Europe PMC
  7. 07
    Al-Jamal RT1 paper · 2025

    Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

    Papers in Europe PMC
  8. 08
    Al-Shamsi HO1 paper · 2022

    Medical Oncology Department, Alzahra Hospital Dubai, Dubai, United Arab Emirates.

    Papers in Europe PMC
  9. 09
    ALAdawi H1 paper · 2022

    Sultan Qaboos University Hospital, Sultanate of Oman.

    Papers in Europe PMC
  10. 10
    AlHarrasi A1 paper · 2022

    Sultan Qaboos Comprehensive Cancer Care and Research Center, Sultanate of Oman.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

medium confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Familial cutaneous telangiectasia and oropharyngeal cancer predisposition syndrome — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Familial cutaneous telangiectasia and oropharyngeal cancer predisposition syndrome" OR "familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome") OR ("ATR syndrome" OR "ATR-related")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Familial cutaneous telangiectasia and oropharyngeal cancer predisposition syndrome" OR "familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (202) is high for prevalence class "<1 / 1 000 000" — confidence capped at medium

Ingested 2026-07-27T12:59:43.020Z